Adragos Pharma recently announced the completion of its acquisition of a commercial-scale sterile fill-finish facility located in Maisons-Alfort, France, from Sanofi. This site is recognized as one of Europe’s largest manufacturing facilities for sterile injectables, featuring industrial-scale capacity for pre-filled syringes, liquids, and lyophilized vials.
The Maisons-Alfort facility is routinely audited by international health authorities, including ANSM, NMPA, MFDS, and ANVISA, ensuring compliance and supporting the global supply of essential injectable medicines. The transfer of site employees to Adragos Pharma brings a wealth of expertise in sterile manufacturing, which is critical for maintaining operational continuity and leveraging the technical excellence established over the years.
This acquisition significantly enhances Adragos’ sterile injectables network, integrating high-volume pre-filled syringe capabilities with existing vial and ampoule filling operations in Jura, Switzerland, and Livron, France. As a result, Adragos is positioned to emerge as a leading contract development and manufacturing organization (CDMO) for sterile injectables in Europe.
Dr. Andreas Raabe, Founder and CEO of Adragos Pharma, emphasized the strategic importance of this acquisition, stating it marks a pivotal moment in the company’s growth trajectory. The integration of the Maisons-Alfort site aligns with Adragos’ strategy to expand its pharmaceutical manufacturing capacity in Europe, aiming to invest in and develop the facility into a premier fill-finish platform.
Moritz Hafner, Partner at FSN Capital, highlighted that this acquisition is a crucial step in positioning Adragos as a key player in the European pharmaceutical CDMO market, enhancing its sterile injectables capabilities and strengthening the team. Philippe Charreau from Sanofi expressed confidence in Adragos’ ability to uphold the site’s legacy of operational excellence, ensuring continued service to patients.
Headquartered in Munich, Germany, Adragos Pharma is focused on developing and manufacturing pharmaceutical products, building a differentiated network across Europe and Japan, particularly in sterile injectables and complex dosage forms.
Get started today with Solo access →
